None listed
Conditions
Interventions
Nalbuphine group:Preoperatively, nalbuphine was administered intravenously at a dose of 0.1 mg/kg
Phloroglucin group:Phloroglucin was administered intravenously preoperatively at doses of 40 mg or 80 mg depending on the patients weight
Sponsors
Affiliated Shunde Hospital of Jinan University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Patients included in the study scheduled for elective general anesthesia for artificial abortion or hysteroscopy, aged 18-45 years, classified as ASA grade I or II, with a BMI ranging from 18 kg/m² to 30 kg/m², and without preoperative respiratory system diseases with normal airway assessment.
Exclusion criteria
Exclusion criteria: Refusal to participate or unsuitability for the trial includes patients with contraindications to anesthesia surgery, those who have used anesthesia, sedatives, or opioid drugs within 24 hours prior to surgery, patients with severe myasthenia gravis, allergies to relevant drugs, liver or kidney dysfunction combined with endocrine or metabolic diseases, patients with mental or neurological disorders, moderate to severe sleep apnea, and those with unstable vital signs due to various serious illnesses.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS scores at 30 minutes, 1 hour, and 24 hours after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in vital signs at different time points;Patient comfort and satisfaction postoperatively;recovery time and adverse reactions post-surgery;Physician satisfaction; | — |
Countries
China
Contacts
Public ContactZhang Zhongqi
Affiliated Shunde Hospital of Jinan University
Outcome results
None listed